查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1790236

北美臨床試驗市場規模、佔有率和趨勢分析報告：按階段、研究設計、適應症、服務、贊助商、國家和細分市場預測，2025 年至 2033 年

North America Clinical Trials Market Size, Share & Trends Analysis Report By Phase, By Study Design, By Indication, By Indication by Study Design, By Service, By Sponsor, By Country, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

北美臨床檢測市場概覽

北美臨床測試市場在 2024 年的價值估計為 430.3 億美元，預計到 2033 年將達到 773.2 億美元，2025 年至 2033 年的複合年成長率為 6.98%。市場成長受到學術研究機構強大生態系統、製藥公司不斷增加的研發資金以及支持大量早期至後期測試的專業委外研發機構(CRO) 的推動。

北美臨床檢測市場由高度發展的研究基礎設施以及眾多始終將臨床開發放在首位的全球製藥、生物技術和醫療設備公司所驅動。梅奧診所、MD 安德森癌症中心和哈佛醫學院等眾多學術研究中心和醫院的存在，促進了早期測試領域的創新和夥伴關係。此外，美國食品藥物管理局 (FDA) 等監管機構為臨床實驗申請 (IND)、孤兒藥認定和自適應測試設計提供了完善的框架，從而降低了進入門檻並加快了臨床開發進度。

此外，產業相關人員、數位健康創新者和患者權益團體之間的合作正在加強。製藥公司不僅在擴展自己的研發開發平臺，還積極與合約研究組織 (CRO) 合作，以簡化試驗設計、場地管理和監管提交流程。這一趨勢使申辦方能夠在不損害資料完整性或病患安全的情況下加快進度。同樣，在倡導基金會和公共衛生宣傳活動的支持下，患者意識和教育的提高正在導致更多的臨床試驗參與，特別是在腫瘤學和罕見疾病等複雜領域。在聯邦指導方針和多元化授權的支持下，朝著更具包容性的招募策略轉變，正在確保臨床結果更好地反映現實世界的人群。

目錄

第1章調查方法與範圍

第2章執行摘要

3. 北美臨床測試市場變數、趨勢和範圍

  • 市場體系展望
    • 母市場展望
    • 輔助市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
    • 市場機會分析
    • 市場問題分析
  • 研發成本分析
    • 主要贊助商研發投資分析（2021-2024）
    • 創業投資與政府資金籌措場景
  • 臨床試驗設計與分析
  • 產業生態系統分析
  • 科技
  • 定價分析
  • 2024年臨床檢測量分析
    • 各地區臨床試驗總數（2024年）
    • 臨床試驗總數（分階段）（2024年）
    • 依研究設計分類的臨床試驗總數（2024 年）
    • 依主要適應症分類的臨床試驗總數（2024年）
  • 臨床測試市場分析工具
    • 波特五力分析
    • PESTEL 與 SWOT 分析

第4章北美臨床測試市場：階段、估計和趨勢分析

  • 細分儀表板
  • 北美臨床測試市場：相位波動分析
  • 階段，2021-2033
  • 第一階段
  • 第二階段
  • 第三階段
  • 第四階段

第5章北美臨床測試市場：按研究設計的估計和趨勢分析

  • 細分儀表板
  • 北美臨床測試市場：研究設計變異分析
  • 依研究設計，2021-2033 年
  • 侵入性
  • 觀察
  • 擴展訪問

第6章北美臨床測試市場：按適應症的估計和趨勢分析

  • 細分儀表板
  • 北美臨床檢測市場：適應症差異分析
  • 依適應症，2021-2033年
  • 自體免疫/炎症
    • 類風濕性關節炎
    • 多發性硬化症
    • 骨關節炎
    • 大腸激躁症（IBS）
    • 其他
  • 疼痛管理
    • 慢性疼痛
    • 急性疼痛
  • 腫瘤學
    • 血癌
    • 固態腫瘤
    • 其他
  • 中樞神經系統症狀
    • 癲癇
    • 帕金森氏症（PD）
    • 亨丁頓舞蹈症
    • 中風
    • 創傷性腦損傷（TBI）
    • 肌萎縮側索硬化症（ALS）
    • 肌肉再生
    • 其他
  • 糖尿病
  • 肥胖
  • 心血管疾病
  • 其他

第7章北美臨床測試市場：適應症、趨勢與研究設計分析

  • 細分儀表板
  • 北美臨床測試市場：研究設計變異分析
  • 依研究設計，依研究設計，2021-2033
  • 自體免疫/炎症
    • 干預測試
    • 觀察測試
    • 擴展訪問檢查
  • 疼痛管理
    • 干預測試
    • 觀察測試
    • 擴展訪問檢查
  • 腫瘤學
    • 干預測試
    • 觀察測試
    • 擴展訪問檢查
  • 中樞神經系統症狀
    • 干預測試
    • 觀察測試
    • 擴展訪問檢查
  • 糖尿病
    • 干預測試
    • 觀察測試
    • 擴展訪問檢查
  • 肥胖
    • 干預測試
    • 觀察測試
    • 擴展訪問檢查
  • 心血管疾病
    • 干預測試
    • 觀察測試
    • 擴展訪問檢查
  • 其他
    • 干預測試
    • 觀察測試
    • 擴展訪問檢查

第 8 章：北美臨床測試市場：按服務進行的估計和趨勢分析

  • 細分儀表板
  • 北美臨床檢測市場：服務差異分析
  • 按服務分類，2021-2033 年
  • 通訊協定設計
  • 區域識別
  • 病患招募
  • 化驗服務
  • 分析測試服務
  • 臨床實驗室數據管理服務
  • 其他

第9章北美臨床測試市場：贊助商的估計和趨勢分析

  • 細分儀表板
  • 北美臨床測試市場：贊助商變更分析
  • 按贊助商，2021-2033 年
  • 製藥和生物製藥公司
  • 醫療設備公司
  • 其他

第 10 章北美臨床測試市場：各國概況、估算與趨勢分析

  • 國家展望
  • 北美臨床檢測市場：國家差異分析
  • 按國家/地區，2021-2033 年
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥

第11章競爭格局

  • 公司分類
    • 創新者
    • 市場領導者
    • 新參與企業
  • 2024年企業市場估值分析
  • 主要企業簡介
    • Pfizer Inc.
    • Merck & Co., Inc.
    • AbbVie Inc.
    • Amgen Inc.
    • Bristol Myers Squibb
    • Gilead Sciences, Inc.
    • Eli Lilly and Company
    • Biogen Inc.
    • Moderna, Inc.
    • Labcorp
    • IQVIA, Inc.
    • Syneos Health
    • PAREXEL International Corporation
    • ICON Plc
    • Thermo Fisher Scientific Inc.
    • Charles River Laboratories International Inc.
    • Medpace Holdings, Inc.
    • Worldwide Clinical Trials
    • Clinipace Inc.
    • Fortrea
  • 其他主要市場參與企業名單
Product Code: GVR-4-68040-202-2

North America Clinical Trials Market Summary

The North America clinical trials market size was estimated at USD 43.03 billion in 2024 and is projected to reach USD 77.32 billion by 2033, growing at a CAGR of 6.98% from 2025 to 2033. The market growth is driven by a robust ecosystem of academic research institutions, growing research and development funding by pharmaceutical companies, and specialized contract research organizations (CROs) that support a high volume of early-to late-phase studies.

The North America clinical trials market is propelled by a highly developed research infrastructure and a concentration of global pharmaceutical, biotechnology, and medical device companies that consistently prioritize clinical development. The presence of several academic research centers and hospitals such as the Mayo Clinic, MD Anderson Cancer Center, and Harvard Medical School is driving the innovation and partnerships in early-stage trials. Moreover, the regulatory agencies such as the U.S. FDA are offering well-established frameworks for Investigational New Drug (IND) applications, Orphan Drug Designations, and adaptive trial designs which is lowering the entry barriers and accelerating the clinical timeline.

Furthermore, increasing collaboration between industry stakeholders, digital health innovators, and patient advocacy groups. Pharmaceutical companies are not only expanding their in-house R&D pipelines but are also actively partnering with CROs to streamline study design, site management, and regulatory submissions. This trend allows sponsors to accelerate timelines without compromising on data integrity or patient safety. Similarly, rising patient awareness and education, often supported by advocacy foundations and public health campaigns has resulted in greater trial participation, particularly in complex areas such as oncology and rare diseases. The shift toward more inclusive enrollment strategies, supported by federal guidelines and diversity mandates, ensures that clinical outcomes better reflect real-world populations.

North America Clinical Trials Market Report Segmentation

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the North America clinical trials market report based on phase, study design, indication, indication by study design, service, sponsor, and country:

  • Phase Outlook (Revenue, USD Million, 2021 - 2033)
  • Phase I
  • Phase II
  • Phase III
  • Phase IV
  • Study Design Outlook (Revenue, USD Million, 2021 - 2033)
  • Interventional Trials
  • Observational Trials
  • Expanded Access Trials
  • Indication Outlook (Revenue, USD Million, 2021 - 2033)
  • Autoimmune/Inflammation
    • Rheumatoid Arthritis
    • Multiple Sclerosis
    • Osteoarthritis
    • Irritable Bowel Syndrome (IBS)
    • Others
  • Pain Management
    • Chronic Pain
    • Acute Pain
  • Oncology
    • Blood Cancer
    • Solid Tumors
    • Others
  • CNS Conditions
    • Epilepsy
    • Parkinson's Disease (PD)
    • Huntington's Disease
    • Stroke
    • Traumatic Brain Injury (TBI)
    • Amyotrophic Lateral Sclerosis (ALS)
    • Muscle Regeneration
    • Others
  • Diabetes
  • Obesity
  • Cardiovascular Diseases
  • Others
  • Indication by Study Design Outlook (Revenue, USD Million, 2021 - 2033)
  • Autoimmune/Inflammation
    • Interventional Trials
    • Observational Trials
    • Expanded Access Trials
  • Pain Management
    • Interventional Trials
    • Observational Trials
    • Expanded Access Trials
  • Oncology
    • Interventional Trials
    • Observational Trials
    • Expanded Access Trials
  • CNS Conditions
    • Interventional Trials
    • Observational Trials
    • Expanded Access Trials
  • Diabetes
    • Interventional Trials
    • Observational Trials
    • Expanded Access Trials
  • Obesity
    • Interventional Trials
    • Observational Trials
    • Expanded Access Trials
  • Cardiovascular Diseases
    • Interventional Trials
    • Observational Trials
    • Expanded Access Trials
  • Others
    • Interventional Trials
    • Observational Trials
    • Expanded Access Trials
  • Service Outlook (Revenue, USD Million, 2021 - 2033)
  • Protocol Designing
  • Site Identification
  • Patient Recruitment
  • Laboratory Services
  • Analytical Testing Services
  • Clinical Trial Data Management Services
  • Others
  • Sponsor Outlook (Revenue, USD Million, 2021 - 2033)
  • Pharmaceutical & Biopharmaceutical Companies
  • Medical Device Companies
  • Others
  • Country Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Value chain based analysis (Model 2)
    • 1.7.3. Multivariate Analysis (Model 3)
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. North America Clinical Trials Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
    • 3.2.3. Market Opportunity Analysis
    • 3.2.4. Market Challenge Analysis
  • 3.3. R&D Spending Analysis
    • 3.3.1. R&D Investment Analysis, by Key Sponsors (2021-2024)
    • 3.3.2. Venture Capital & Government Funding Scenario
  • 3.4. Clinical Trials Design Analysis
  • 3.5. Industry Ecosystem Analysis
  • 3.6. Technology Landscape
  • 3.7. Pricing Analysis
  • 3.8. Clinical Trial Volume Analysis, 2024
    • 3.8.1. Total Number of Clinical Trials, By Region (2024)
    • 3.8.2. Total Number of Clinical Trials, By Phase (2024)
    • 3.8.3. Total Number of Clinical Trials, By Study Design (2024)
    • 3.8.4. Total Number of Clinical Trials, By Key Indication (2024)
  • 3.9. Clinical Trials Market Analysis Tools
    • 3.9.1. Porter's Five Forces Analysis
    • 3.9.2. PESTEL by SWOT Analysis

Chapter 4. North America Clinical Trials Market: Phase Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. North America Clinical Trials Market: Phase Movement Analysis
  • 4.3. North America Clinical Trials Market Estimates and Forecasts, by Phase, 2021 - 2033 (USD Million)
  • 4.4. Phase I
    • 4.4.1. Phase I Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5. Phase II
    • 4.5.1. Phase II Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6. Phase III
    • 4.6.1. Phase III Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.7. Phase IV
    • 4.7.1. Phase IV Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. North America Clinical Trials Market: Study Design Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. North America Clinical Trials Market: Study Design Movement Analysis
  • 5.3. North America Clinical Trials Market Estimates and Forecasts, by Study Design, 2021 - 2033 (USD Million)
  • 5.4. Interventional
    • 5.4.1. Interventional Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5. Observational
    • 5.5.1. Observational Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.6. Expanded Access
    • 5.6.1. Expanded Access Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. North America Clinical Trials Market: Indication Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. North America Clinical Trials Market: Indication Movement Analysis
  • 6.3. North America Clinical Trials Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
  • 6.4. Autoimmune/Inflammation
    • 6.4.1. Autoimmune/Inflammation Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.2. Rheumatoid Arthritis
      • 6.4.2.1. Rheumatoid Arthritis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.3. Multiple Sclerosis
      • 6.4.3.1. Multiple Sclerosis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.4. Osteoarthritis
      • 6.4.4.1. Osteoarthritis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.5. Irritable Bowel Syndrome (IBS)
      • 6.4.5.1. Irritable Bowel Syndrome (IBS) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.6. Others
      • 6.4.6.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Pain Management
    • 6.5.1. Pain Management Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.2. Chronic Pain
      • 6.5.2.1. Chronic Pain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.3. Acute Pain
      • 6.5.3.1. Acute Pain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6. Oncology
    • 6.6.1. Oncology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.2. Blood Cancer
      • 6.6.2.1. Blood Cancer Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.3. Solid Tumors
      • 6.6.3.1. Solid Tumors Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.4. Others
      • 6.6.4.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7. CNS Conditions
    • 6.7.1. CNS Conditions Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.2. Epilepsy
      • 6.7.2.1. Epilepsy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.3. Parkinson's Disease (PD)
      • 6.7.3.1. Parkinson's Disease (PD) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.4. Huntington's Disease
      • 6.7.4.1. Huntington's Disease Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.5. Stroke
      • 6.7.5.1. Stroke Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.6. Traumatic Brain Injury (TBI)
      • 6.7.6.1. Traumatic Brain Injury (TBI) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.7. Amyotrophic Lateral Sclerosis (ALS)
      • 6.7.7.1. Amyotrophic Lateral Sclerosis (ALS) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.8. Muscle Regeneration
      • 6.7.8.1. Muscle Regeneration Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.9. Others
      • 6.7.9.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8. Diabetes
    • 6.8.1. Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.9. Obesity
    • 6.9.1. Obesity Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.10. Cardiovascular Diseases
    • 6.10.1. Cardiovascular Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.11. Others
    • 6.11.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. North America Clinical Trials Market: Indication by Study Design Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. North America Clinical Trials Market: Indication by Study Design Movement Analysis
  • 7.3. North America Clinical Trials Market Estimates and Forecasts, by Indication by Study Design, 2021 - 2033 (USD Million)
  • 7.4. Autoimmune/Inflammation
    • 7.4.1. Autoimmune/Inflammation Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.2. Interventional Trials
      • 7.4.2.1. Interventional Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.3. Observational Trials
      • 7.4.3.1. Observational Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.4. Expanded Access Trials
      • 7.4.4.1. Expanded Access Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5. Pain Management
    • 7.5.1. Pain Management Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.2. Interventional Trials
      • 7.5.2.1. Interventional Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.3. Observational Trials
      • 7.5.3.1. Observational Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.4. Expanded Access Trials
      • 7.5.4.1. Expanded Access Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6. Oncology
    • 7.6.1. Oncology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.2. Interventional Trials
      • 7.6.2.1. Interventional Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.3. Observational Trials
      • 7.6.3.1. Observational Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.4. Expanded Access Trials
      • 7.6.4.1. Expanded Access Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7. CNS Conditions
    • 7.7.1. CNS Conditions Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.2. Interventional Trials
      • 7.7.2.1. Interventional Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.3. Observational Trials
      • 7.7.3.1. Observational Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.4. Expanded Access Trials
      • 7.7.4.1. Expanded Access Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8. Diabetes
    • 7.8.1. Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.2. Interventional Trials
      • 7.8.2.1. Interventional Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.3. Observational Trials
      • 7.8.3.1. Observational Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.4. Expanded Access Trials
      • 7.8.4.1. Expanded Access Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.9. Obesity
    • 7.9.1. Obesity Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.9.2. Interventional Trials
      • 7.9.2.1. Interventional Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.9.3. Observational Trials
      • 7.9.3.1. Observational Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.9.4. Expanded Access Trials
      • 7.9.4.1. Expanded Access Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.10. Cardiovascular Diseases
    • 7.10.1. Cardiovascular Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.10.2. Interventional Trials
      • 7.10.2.1. Interventional Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.10.3. Observational Trials
      • 7.10.3.1. Observational Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.10.4. Expanded Access Trials
      • 7.10.4.1. Expanded Access Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.11. Others
    • 7.11.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.11.2. Interventional Trials
      • 7.11.2.1. Interventional Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.11.3. Observational Trials
      • 7.11.3.1. Observational Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.11.4. Expanded Access Trials
      • 7.11.4.1. Expanded Access Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. North America Clinical Trials Market: Service Estimates & Trend Analysis

  • 8.1. Segment Dashboard
  • 8.2. North America Clinical Trials Market: Service Movement Analysis
  • 8.3. North America Clinical Trials Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • 8.4. Protocol Designing
    • 8.4.1. Protocol Designing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5. Site Identification
    • 8.5.1. Site Identification Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6. Patient Recruitment
    • 8.6.1. Patient Recruitment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7. Laboratory Services
    • 8.7.1. Laboratory Services Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.8. Analytical Testing Services
    • 8.8.1. Analytical Testing Services Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.9. Clinical Trial Data Management Services
    • 8.9.1. Clinical Trial Data Management Services Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.10. Others
    • 8.10.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. North America Clinical Trials Market: Sponsor Estimates & Trend Analysis

  • 9.1. Segment Dashboard
  • 9.2. North America Clinical Trials Market: Sponsor Movement Analysis
  • 9.3. North America Clinical Trials Market Estimates and Forecasts, by Sponsor, 2021 - 2033 (USD Million)
  • 9.4. Pharmaceutical & Biopharmaceutical Companies
    • 9.4.1. Pharmaceutical & Biopharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.5. Medical Device Companies
    • 9.5.1. Medical Device Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.6. Others
    • 9.6.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 10. North America Clinical Trials Market: Country Estimates & Trend Analysis

  • 10.1. Country Outlook
  • 10.2. North America Clinical Trials Market: Country Movement Analysis
  • 10.3. North America Clinical Trials Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Million)
  • 10.4. North America
    • 10.4.1. North America Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 10.4.2. U.S.
      • 10.4.2.1. Key Country Dynamics
      • 10.4.2.2. Competitive Scenario
      • 10.4.2.3. Regulatory Framework
      • 10.4.2.4. U.S. Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 10.4.3. Canada
      • 10.4.3.1. Key Country Dynamics
      • 10.4.3.2. Competitive Scenario
      • 10.4.3.3. Regulatory Framework
      • 10.4.3.4. Canada Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 10.4.4. Mexico
      • 10.4.4.1. Key Country Dynamics
      • 10.4.4.2. Competitive Scenario
      • 10.4.4.3. Regulatory Framework
      • 10.4.4.4. Mexico Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 11. Competitive Landscape

  • 11.1. Company Categorization
    • 11.1.1. Innovators
    • 11.1.2. Market Leaders
    • 11.1.3. Emerging Players
  • 11.2. Company Market Assessment Analysis, 2024
  • 11.3. Key Company Profiles
    • 11.3.1. Pfizer Inc.
      • 11.3.1.1. Company Overview
      • 11.3.1.2. Financial Performance
      • 11.3.1.3. Service Benchmarking
      • 11.3.1.4. Strategic Initiatives
    • 11.3.2. Merck & Co., Inc.
      • 11.3.2.1. Company Overview
      • 11.3.2.2. Financial Performance
      • 11.3.2.3. Service Benchmarking
      • 11.3.2.4. Strategic Initiatives
    • 11.3.3. AbbVie Inc.
      • 11.3.3.1. Company Overview
      • 11.3.3.2. Financial Performance
      • 11.3.3.3. Service Benchmarking
      • 11.3.3.4. Strategic Initiatives
    • 11.3.4. Amgen Inc.
      • 11.3.4.1. Company Overview
      • 11.3.4.2. Financial Performance
      • 11.3.4.3. Service Benchmarking
      • 11.3.4.4. Strategic Initiatives
    • 11.3.5. Bristol Myers Squibb
      • 11.3.5.1. Company Overview
      • 11.3.5.2. Financial Performance
      • 11.3.5.3. Service Benchmarking
      • 11.3.5.4. Strategic Initiatives
    • 11.3.6. Gilead Sciences, Inc.
      • 11.3.6.1. Company Overview
      • 11.3.6.2. Financial Performance
      • 11.3.6.3. Service Benchmarking
      • 11.3.6.4. Strategic Initiatives
    • 11.3.7. Eli Lilly and Company
      • 11.3.7.1. Company Overview
      • 11.3.7.2. Financial Performance
      • 11.3.7.3. Service Benchmarking
      • 11.3.7.4. Strategic Initiatives
    • 11.3.8. Biogen Inc.
      • 11.3.8.1. Company Overview
      • 11.3.8.2. Financial Performance
      • 11.3.8.3. Service Benchmarking
      • 11.3.8.4. Strategic Initiatives
    • 11.3.9. Moderna, Inc.
      • 11.3.9.1. Company Overview
      • 11.3.9.2. Financial Performance
      • 11.3.9.3. Service Benchmarking
      • 11.3.9.4. Strategic Initiatives
    • 11.3.10. Labcorp
      • 11.3.10.1. Company Overview
      • 11.3.10.2. Financial Performance
      • 11.3.10.3. Service Benchmarking
      • 11.3.10.4. Strategic Initiatives
    • 11.3.11. IQVIA, Inc.
      • 11.3.11.1. Company Overview
      • 11.3.11.2. Financial Performance
      • 11.3.11.3. Service Benchmarking
      • 11.3.11.4. Strategic Initiatives
    • 11.3.12. Syneos Health
      • 11.3.12.1. Company Overview
      • 11.3.12.2. Financial Performance
      • 11.3.12.3. Service Benchmarking
      • 11.3.12.4. Strategic Initiatives
    • 11.3.13. PAREXEL International Corporation
      • 11.3.13.1. Company Overview
      • 11.3.13.2. Financial Performance
      • 11.3.13.3. Service Benchmarking
      • 11.3.13.4. Strategic Initiatives
    • 11.3.14. ICON Plc
      • 11.3.14.1. Company Overview
      • 11.3.14.2. Financial Performance
      • 11.3.14.3. Service Benchmarking
      • 11.3.14.4. Strategic Initiatives
    • 11.3.15. Thermo Fisher Scientific Inc.
      • 11.3.15.1. Company Overview
      • 11.3.15.2. Financial Performance
      • 11.3.15.3. Service Benchmarking
      • 11.3.15.4. Strategic Initiatives
    • 11.3.16. Charles River Laboratories International Inc.
      • 11.3.16.1. Company Overview
      • 11.3.16.2. Financial Performance
      • 11.3.16.3. Service Benchmarking
      • 11.3.16.4. Strategic Initiatives
    • 11.3.17. Medpace Holdings, Inc.
      • 11.3.17.1. Company Overview
      • 11.3.17.2. Financial Performance
      • 11.3.17.3. Service Benchmarking
      • 11.3.17.4. Strategic Initiatives
    • 11.3.18. Worldwide Clinical Trials
      • 11.3.18.1. Company Overview
      • 11.3.18.2. Financial Performance
      • 11.3.18.3. Service Benchmarking
      • 11.3.18.4. Strategic Initiatives
    • 11.3.19. Clinipace Inc.
      • 11.3.19.1. Company Overview
      • 11.3.19.2. Financial Performance
      • 11.3.19.3. Service Benchmarking
      • 11.3.19.4. Strategic Initiatives
    • 11.3.20. Fortrea
      • 11.3.20.1. Company Overview
      • 11.3.20.2. Financial Performance
      • 11.3.20.3. Service Benchmarking
      • 11.3.20.4. Strategic Initiatives
  • 11.4. List of Other Key Market Players

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 North America Clinical Trials Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Million)
  • Table 4 North America Clinical Trials Market Estimates and Forecasts, by Phase, 2021 - 2033 (USD Million)
  • Table 5 North America Clinical Trials Market Estimates and Forecasts, by Study Design, 2021 - 2033 (USD Million)
  • Table 6 North America Clinical Trials Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 7 North America Clinical Trials Market Estimates and Forecasts, Indication by Study Design, 2021 - 2033 (USD Million)
  • Table 8 North America Clinical Trials Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 9 North America Clinical Trials Market Estimates and Forecasts, by Sponsor, 2021 - 2033 (USD Million)
  • Table 10 U.S. Clinical Trials Market Estimates and Forecasts, by Phase, 2021 - 2033 (USD Million)
  • Table 11 U.S. Clinical Trials Market Estimates and Forecasts, by Study Design, 2021 - 2033 (USD Million)
  • Table 12 U.S. Clinical Trials Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 13 U.S. Clinical Trials Market Estimates and Forecasts, Indication by Study Design, 2021 - 2033 (USD Million)
  • Table 14 U.S. Clinical Trials Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 15 U.S. Clinical Trials Market Estimates and Forecasts, by Sponsor, 2021 - 2033 (USD Million)
  • Table 16 Canada Clinical Trials Market Estimates and Forecasts, by Phase, 2021 - 2033 (USD Million)
  • Table 17 Canada Clinical Trials Market Estimates and Forecasts, by Study Design, 2021 - 2033 (USD Million)
  • Table 18 Canada Clinical Trials Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 19 Canada Clinical Trials Market Estimates and Forecasts, Indication by Study Design, 2021 - 2033 (USD Million)
  • Table 20 Canada Clinical Trials Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 21 Canada Clinical Trials Market Estimates and Forecasts, by Sponsor, 2021 - 2033 (USD Million)
  • Table 22 Mexico Clinical Trials Market Estimates and Forecasts, by Phase, 2021 - 2033 (USD Million)
  • Table 23 Mexico Clinical Trials Market Estimates and Forecasts, by Study Design, 2021 - 2033 (USD Million)
  • Table 24 Mexico Clinical Trials Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 25 Mexico Clinical Trials Market Estimates and Forecasts, Indication by Study Design, 2021 - 2033 (USD Million)
  • Table 26 Mexico Clinical Trials Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 27 Mexico Clinical Trials Market Estimates and Forecasts, by Sponsor, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Clinical Trials Market Segmentation
  • Fig. 2 Market Research Process
  • Fig. 3 Information Procurement
  • Fig. 4 Primary Research Pattern
  • Fig. 5 Market Research Approaches
  • Fig. 6 Value Chain-Based Sizing & Forecasting
  • Fig. 7 Market Formulation & Validation
  • Fig. 8 Market Dynamics
  • Fig. 9 Market Driver Relevance Analysis (Current & Future Impact)
  • Fig. 10 Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 11 Porter's Five Forces Analysis
  • Fig. 12 PESTEL by SWOT Analysis
  • Fig. 13 North America Phase I Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 14 North America Phase II Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 15 North America Phase III Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 16 North America Phase IV Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 17 North America Interventional Trials Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 18 North America Observational Trials Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 19 North America Expanded Access Trials Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 20 North America Autoimmune/Inflammation Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 21 North America Rheumatoid Arthritis Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 22 North America Multiple Sclerosis Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 23 North America Osteoarthritis Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 24 North America Irritable Bowel Syndrome (IBS) Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 25 North America Others Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 26 North America Pain Management Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 27 North America Chronic Pain Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 28 North America Acute Pain Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 29 North America Oncology Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 30 North America Blood Cancer Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 31 North America Solid Tumors Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 32 North America Others Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 33 North America CNS Conditions Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 34 North America Epilepsy Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 35 North America Parkinson's Disease (PD) Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 36 North America Huntington's Disease Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 37 North America Stroke Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 38 North America Traumatic Brain Injury (TBI) Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 39 North America Amyotrophic Lateral Sclerosis (ALS) Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 40 North America Muscle Regeneration Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 41 North America Others Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 42 North America Diabetes Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 43 North America Obesity Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 44 North America Cardiovascular Diseases Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 45 North America Others Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 46 North America Autoimmune/Inflammation Interventional Trials Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 47 North America Autoimmune/Inflammation Observational Trials Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 48 North America Autoimmune/Inflammation Expanded Access Trials Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 49 North America Pain Management Interventional Trials Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 50 North America Pain Management Observational Trials Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 51 North America Pain Management Expanded Access Trials Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 52 North America Oncology Interventional Trials Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 53 North America Oncology Observational Trials Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 54 North America Oncology Expanded Access Trials Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 55 North America CNS Conditions Interventional Trials Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 56 North America CNS Conditions Observational Trials Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 57 North America CNS Conditions Expanded Access Trials Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 58 North America Diabetes Interventional Trials Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 59 North America Diabetes Observational Trials Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 60 North America Diabetes Expanded Access Trials Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 61 North America Obesity Interventional Trials Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 62 North America Obesity Observational Trials Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 63 North America Obesity Expanded Access Trials Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 64 North America Cardiovascular Diseases Interventional Trials Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 65 North America Cardiovascular Diseases Observational Trials Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 66 North America Cardiovascular Diseases Expanded Access Trials Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 67 North America Others Interventional Trials Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 68 North America Others Observational Trials Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 69 North America Others Expanded Access Trials Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 70 North America Protocol Designing Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 71 North America Site Identification Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 72 North America Patient Recruitment Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 73 North America Laboratory Services Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 74 North America Analytical Testing Services Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 75 North America Clinical Trial Data Management Services Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 76 North America Others Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 77 North America Pharmaceutical & Biopharmaceutical Companies Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 78 North America Medical Device Companies Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 79 North America Others Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 80 Country Outlook, 2024 & 2033
  • Fig. 81 US Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 82 Canada Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 83 Mexico Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)